美山 貴彦

Medicine & Life Sciences

1. Gastrointestinal Microbiome 100%
2. Cell Transplantation 97%
3. Mucus 95%
4. Melphalan 91%
5. ranimustine 81%
6. Microbiota 77%
7. Plasmablastic Lymphoma 74%
8. AIDS-Related Lymphoma 71%
9. Graft vs Host Disease 71%
10. Thrombotic Microangiopathies 61%
11. Nivolumab 61%
12. T-Cell Antigen Receptor 61%
13. Busulfan 58%
14. fludarabine 58%
15. Haploinsufficiency 57%
16. Bacteroides 57%
17. Ectoderm 56%
18. Pancytopenia 56%
19. Bacteroides thetaiotaomicron 55%
20. Carbapenems 52%
21. Highly Active Antiretroviral Therapy 50%
22. Hematologic Neoplasms 50%
23. Hematopoiesis 49%
24. Allogeneic Cells 48%
25. Adenocarcinoma of Lung 48%
26. Stem Cell Transplantation 47%
27. Cytomegalovirus 44%
28. Hematopoietic Stem Cells 44%
29. Xylose 44%
30. Embryonic Development 41%
31. Meropenem 41%
32. Cisplatin 40%
33. Mucins 40%
34. T-Lymphocytes 37%
35. Plasma Exchange 36%
36. Hepatocellular Carcinoma 36%
37. T-Lymphocyte Subsets 35%
38. High-Throughput Nucleotide Sequencing 35%
39. Disseminated Intravascular Coagulation 35%
40. Thrombocytopenia 35%
41. varespladib methyl 35%
42. Fever 33%
43. Allergy and Immunology 32%
44. Polysaccharides 31%
45. Maintenance 31%
46. Neoplasms 31%
47. Diet 30%
48. Propionates 29%
49. Caloric Restriction 28%
50. Cytarabine 25%